Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01739660 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
A Phase 1 study, sponsored by Savient Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01739660 is a Phase 1 study that has completed, run by Savient Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT01739660, a Phase 1 study, has completed, sponsored by Savient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase administered to hemodialysis patients. A single dose of pegloticase will be administered intravenously to male or female hemodialysis patients (N = 12) starting 3 hour prior to dialysis. The study consists of a Screening Period, a Treatment Period, and Follow up Period.
Interventions
- DRUG Pegloticase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01739660
The ClinicalTrials.gov registry entry for NCT01739660 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Savient Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegloticase is the first listed.
NCT01739660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01739660 about?
NCT01739660 is a clinical study titled "Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis". This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase administered to hemodialysis patients. A single dose of pegloticase will be administered intravenously to male or female hemodialysis patients (N = 12) starting 3 hour prior to dialysis. The study consists of a ...
What is the current status of trial NCT01739660?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01739660?
The interventions under investigation include: Pegloticase (DRUG).
Who is sponsoring clinical trial NCT01739660?
This trial is sponsored by Savient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.